comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 17:44:27 - browse：8476

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Personalized medicine goes far beyond genetics

focus

WSS

ChatGPT in medicine: STAT answers readers' burning questions

Duchenne breakthrough therapy leaves behind pioneering families

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

How to ethically and practically extend health care to all

How to ethically and practically extend health care to all

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

focus

comprehensive

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

H.R. 3 is the wrong path to lower drug costs

Peter Hotez and the public health issue of online harassment

In Memoriam: Notable people who died in 2023

Medicare details structure of new drug price negotiation program

Hepatitis C has a cure — but many Americans still lack access to it

23andMe had bad news about my health. I wish a person had delivered it

Medicare slashes safety net hospital payments by nearly $1 billion

Hepatitis C has a cure — but many Americans still lack access to it

Heart attack and stroke risk calculators need revising

Wikipedia

Sports medicine is finally prioritizing gender equality

A controversial new treatment promises to make little people taller

What does generative AI mean for health care? We asked experts

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Dobbs anniversary: the lost opportunity of abortion as health care

2 officers injured in shooting in Orlando, police say

hotspot

hotspot

focus

explore